<DOC>
	<DOCNO>NCT00757588</DOCNO>
	<brief_summary>The purpose study compare effect saxagliptin placebo add-on therapy insulin insulin metformin improve glycemic control 24 52 week .</brief_summary>
	<brief_title>Safety Efficacy Saxagliptin Plus Insulin With Without Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus Must take stable dose basal premixed insulin 8 week longer prior screen If take metformin , must take daily dose 8 week longer prior screen Insulin type intermediate longacting ( basal ) premixed ( premixed formulation may include short rapidacting insulin 1 component ) . Inadequate glycemic control ( A1C 7.5 % 11.0 % , inclusive ) Body mass index 45 kg/mÂ² lower Fasting Cpeptide level 0.8 ng/mL high Symptoms poorly control diabetes , include limited mark polyuria polydipsia great 10 % weight loss last 3 month prior screen sign symptom History diabetic ketoacidosis hyperosmolar nonketotic coma Women childbearing potential unable unwilling use acceptable birth control Women pregnant breastfeed Active liver disease Anemia Chronic repeat intermittent corticosteroid treatment ( participant receive stable dos replacement corticosteroid ( except dexamethasone ) therapy may enrol ) Use short rapidacting insulin Significant cardiovascular history define : myocardial infarction , coronary angioplasty bypass graft , valvular disease repair , unstable angina pectoris , transient ischemic attack , cerebrovascular accident Congestive heart failure Unstable rapidly progress renal disease History alcohol drug abuse within previous year History hemoglobinopathy Unstable major psychiatric disorder Immunocompromised status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>